BioAscent Discovery Ltd is a leading provider of integrated drug discovery services based at the former Organon / Merck Sharpe and Dohme R&D site in Newhouse, Scotland.
Their drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management. BioAscent’s team of expert scientists has experience of successfully working from assay development through to pre-clinical and clinical candidates across all biological target classes and major therapeutic indications.
As part of its compound management service, BioAscent currently holds and manages over 1 million compounds for customers, in both liquid and solid formats. Through the Compound Cloud service, the company provides rapid access to an IP-free library of 125,000 lead like compounds in screening-ready format.
XenoGesis works together with BioAscent to combine capabilities and expertise across the key disciplines of in vitro biosciences, DMPK and medicinal chemistry.
Using a tailored, iterative design-make-test approach, they work from target validation onwards to develop a compound for candidate nomination.
Their combined track record and specific experience in generating quality hit and lead series that have maximum chance of success in lead optimisation and beyond is unrivalled.